Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLPHINS-2: Phase 2 Study of HM15912 in Adults with Short Bowel Syndrome-associated Intestinal Failure
2021-000176-11Phase 2Active
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sonefpeglutide in Short bowel syndrome-associated intestinal failure (SBS-IF) and short bowel syndrome (SBS), sponsored by Hanmi Pharmaceutical. Primary endpoints: Safety and tolerability of HM15912 after multiple subcutaneous doses for 24 weeks and Pharmacodynamic profile of HM15912. Started May 2021; status: active.
02
Drugs
sonefpeglutide
03
Conditions
Short bowel syndrome-associated intestinal failure (SBS-IF)short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2021-000176-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000176-11.